Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Analyzing Pharma Stock Giants: JNJ, MRK, and ABBV

The pharmaceutical industry is set for long-term growth due to growing demand for quality drugs and therapies, an aging population, and the rise in lifestyle-related diseases. Now, let's explore the investment potential of industry giants Merck & Co (MRK), Johnson & Johnson (JNJ), and AbbVie (ABBV). Keep reading.

StockNews.com

Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead

Arcellx and Gilead's Kite division deepened their collaboration in cancer treatments on Wednesday. ACLX stock rocketed into a breakout.

Investors Business Daily

Azenta Surges, Nearing Breakout, After Ducking Out Of A Looming Proxy Fight

AZTA stock jumped early Tuesday on strong earnings and after saying an activist investor won't push for any more seats this year.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Vertex Pharmaceuticals (VRTX) Post-Earnings Analysis: Is It Time to Buy the Stock?

After a solid third-quarter earnings report, does Vertex Pharmaceuticals (VRTX) deserve a place in your portfolio? Let’s look at its financial metrics to gauge its prospects….

StockNews.com

Amylyx Crashes 32% On A Quarterly Report That Doesn't Bode Well For 2024

Amylyx missed Wall Street's expectations on Thursday amid struggles for its amyotrophic lateral sclerosis drug, and AMLX stock crashed.

Investors Business Daily

This Health Care Play Breaks Out After Doubling The Market's Gains

MEDP stock has broken out of a cup with handle and has climbed 29% this year. Medpace offers clinical trial and medical device support.

Investors Business Daily

Becton Dickinson & Co. (BDX) Earnings Moves: A Buy or Sell for Investors?

Becton Dickinson & Co. (BDX) is expected to report steady growth for its fiscal fourth quarter ended September 2023, scheduled to be released on November 9. While the stock is witnessing weakness over the past month, will the quarterly report be able to spur a rally? Read on.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Gilead Tumbles After An Unpredictable Element Drove Its Third-Quarter Beat

Investors hammered GILD stock on Wednesday after Gilead beat third-quarter expectations on the back of its Covid treatment, Veklury.

Investors Business Daily

BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake

Activist investor Elliott has reportedly built a $1 billion stake in BioMarin Pharmaceutical, Reuters reported Tuesday as BMRN stock rocketed.

Investors Business Daily

Biogen (BIIB) Earnings Spotlight: Is the Biotech Stock a Buy or Sell?

Biotech major Biogen (BIIB) will report its third-quarter results on November 8. Its EPS and revenue are expected to decline year-over-year. However, the FDA approvals for new drugs received by the company this year will likely support its long-term growth. Let’s discuss the potential road ahead for the stock….

StockNews.com

Gilead Sciences (GILD) Earnings Forecast and Gameplan

Gilead Sciences (GILD) boasts an impressive product portfolio and has surpassed the consensus estimate on the topline in each of the trailing four quarters. With the company gearing up to post its third quarter results, is GILD a wise investment now? Read on.

StockNews.com

Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi

Celldex could rival a key Regeneron drug, an analyst said Monday as CLDX stock rocketed on the results of multiple studies.

Investors Business Daily

Michelle Mone admits involvement with 'VIP lane' PPE firm for the first time

TORY peer Michelle Mone has admitted her involvement with a “VIP lane” PPE company for the first time.

The National (Scotland)

Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners

Cathie Wood's flagship Ark Innovation ETF ARKK just had its best week ever thanks to Roku, DraftKings, Palantir and other huge winners on big news.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Pharma Stocks Providing Consistent Gains for Investors

The pharmaceutical industry is anticipated to be bolstered due to the increasing demand for chronic disease management and the rising requirements of an aging demographic. Given the industry’s solid prospects, investors could buy quality pharma stocks Eton Pharmaceuticals (ETON), Ipsen S.A. (IPSEY), and Merck & Co. (MRK) for consistent gains.…

StockNews.com

3 Pharma Stocks to Capitalize on With Potential Upside

The pharma industry’s prospects look bright, thanks to rising demand for innovative drugs. Thus, pharma stocks with potential upside, like GSK plc (GSK), Johnson & Johnson (JNJ), and Bristol-Myers Squibb Company (BMY), could be wise investments to capitalize on right now. Read on….

The Independent UK

Minister vows to be ‘robust’ in fighting for drugs policy funding

Elena Whitham rejected claims there has been a real-terms cut in investment.

StockNews.com

3 Top-Rated Pharma Stocks Worth Including in Your November Portfolio

The pharmaceutical sector is booming with increasing global healthcare demands and technological progress. Hence, top-rated pharma stocks Dr. Reddy’s (RDY), Novo Nordisk (NVO), and AbbVie (ABBV) might be solid additions to one’s portfolio in November. Read more.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Moderna Tumbles As Light Guidance And Steep Losses Overshadow Sales Beat

Moderna stock tumbled Thursday after the Covid vaccine maker handily beat third-quarter sales forecasts, but issued light guidance.

StockNews.com

Regeneron Pharmaceuticals (REGN) Earnings Analysis -- Should Investors Brace for Impact?

Regeneron Pharmaceuticals (REGN) has an impressive revenue and earnings surprise history. So, as the company gears up to post its third-quarter report, is REGN the right pick? Read on.

Investors Business Daily

Cardinal Health, Cencora Break Out With Assist From GLP-1 Demand

Cardinal Health and Cencora both broke out after topping earnings estimates as both drug-distributors got a boost from GLP-1 weight-loss drugs.

StockNews.com

Eli Lilly & Co. (LLY) Earnings Forecast

Drugmaker Eli Lilly and Company (LLY) is scheduled to release its third-quarter results soon. While its revenue is expected to rise sharply over the prior-year quarter, its earnings are expected to decline. So, how should investors position themselves before the results are out? Read on to learn more….

The Independent UK

These 27 eye products could lead to infections and vision loss, FDA warns

If you find one of the products in your home you need to dispose of it immediately, the FDA says

Investors Business Daily

Verve Stock Soars On $250 Million Eli Lilly Deal

Lilly will pay $250 million to Beam for the rights to three gene-editing drugs from Verve. VERV stock and Beam stock skyrocketed.

The Street

Pfizer posts narrower Q3 loss amid slumping Covid vaccine sales

Pfizer, which warned of a $5.5 billion writedown of its Covid treatment inventories earlier this month, posted a narrower-than-expected third quarter loss Tuesday.

1 … 23 24 25 26

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Amyotrophic lateral sclerosis

14 stories

Places

United States

247,280 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.